Stocktoria
Coherus Oncology, Inc. CHRS
Coherus Oncology, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value ($4.03); a green figure means the price is below it.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
P / E vs its own history
Coherus Oncology, Inc. trades at about 0.8× earnings — below its 10-year norm (10-year range 1.5×–14.7×, median 11.6×).
Shaded band = 10-year range (1.5×–14.7×); dot = today's 0.8×.
Historical P/E = month-end price near each fiscal year-end ÷ that year's EPS. A read on whether the stock is cheap or dear relative to how it has typically been valued — not a forecast.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -429.5% | -756.6% | -79.0% | -121.7% | -80.8% | 32.9% | 30.3% | — | -14918.8% | -61.0% |
| Net margin | 398.4% | 108.0% | -92.5% | -138.2% | -87.9% | 27.8% | 25.2% | — | -15306.6% | -67.0% |
| FCF margin | — | — | -68.1% | -115.2% | -11.9% | 30.9% | 7.5% | — | -13165.7% | -136.3% |
| Return on assets | 65.0% | 6.4% | -37.8% | -60.7% | -42.3% | 15.7% | 22.0% | -210.5% | -146.5% | -71.3% |
| Return on equity | 275.4% | -21.6% | 123.0% | 212.3% | -293.8% | 47.1% | 85.4% | 542.5% | -780.0% | -620.3% |
| Debt / equity | — | — | — | — | — | — | 0.70× | -0.00× | — | — |
| Current ratio | 1.47 | 1.21 | 1.43 | 2.75 | 3.64 | 5.27 | 2.98 | 2.54 | 5.12 | 2.86 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.